{"disease":{"id":"ventricular","name":"ventricular"},"drugs":{"marketed":[{"drug_id":"valsartan","indication_name":"Left ventricular cardiac dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diovan","generic_name":"VALSARTAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Type-1 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker [EPC]","quality_score":10,"revenue":"447","mechanism":"Diovan works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure."},{"drug_id":"flecainide","indication_name":"Paroxysmal Supraventricular Tachycardias (PSVT)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tambocor","generic_name":"FLECAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":59,"revenue":null,"mechanism":""},{"drug_id":"flecainide","indication_name":"Documented Ventricular Arrhythmias","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tambocor","generic_name":"FLECAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":59,"revenue":null,"mechanism":""},{"drug_id":"esmolol","indication_name":"Control of ventricular rate in supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brevibloc In Plastic Container","generic_name":"ESMOLOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":63,"revenue":null,"mechanism":"Brevibloc works by blocking the beta-1 adrenergic receptor, which reduces the heart's response to stress and increases heart rate."},{"drug_id":"enalapril-maleate","indication_name":"Asymptomatic Left Ventricular Dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vasotec","generic_name":"ENALAPRIL MALEATE","company_name":"Azurity","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor","quality_score":67,"revenue":null,"mechanism":"Vasotec works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor."},{"drug_id":"mexiletine","indication_name":"Ventricular Arrhythmias","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mexitil","generic_name":"MEXILETINE","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2B","drug_class":"Antiarrhythmic","quality_score":66,"revenue":null,"mechanism":"Mexitil works by blocking abnormal electrical signals in the heart to restore a normal heartbeat."},{"drug_id":"mexiletine-hydrochloride","indication_name":"Ventricular Arrhythmias","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MEXILETINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"sodium channels","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Mexiletine, an oral antiarrhythmic, reduces ventricular arrhythmias by inhibiting sodium currents and altering refractory periods."},{"drug_id":"flecainide-acetate","indication_name":"Paroxysmal Supraventricular Tachycardias (PSVT)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLECAINIDE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"flecainide-acetate","indication_name":"Documented Ventricular Arrhythmias","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLECAINIDE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"encainide","indication_name":"Ventricular premature beats","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ENCAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Sodium channel protein type 5 subunit alpha","drug_class":"encainide","quality_score":28,"revenue":null,"mechanism":""},{"drug_id":"diovan","indication_name":"Left ventricular cardiac dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Diovan","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Platelet glycoprotein VI, Type-1 angiotensin II receptor, Angiotensin II receptor (AT-1) type-1","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"ajmaline","indication_name":"Supraventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ajmalin","generic_name":"AJMALINE","company_name":"","drug_phase":"phase_3","molecular_target":"Potassium voltage-gated channel subfamily A member 5","drug_class":"ajmaline","quality_score":36,"revenue":null,"mechanism":"Ajmaline works by blocking potassium channels in the heart to help regulate heart rhythm."},{"drug_id":"ajmaline","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ajmalin","generic_name":"AJMALINE","company_name":"","drug_phase":"phase_3","molecular_target":"Potassium voltage-gated channel subfamily A member 5","drug_class":"ajmaline","quality_score":36,"revenue":null,"mechanism":"Ajmaline works by blocking potassium channels in the heart to help regulate heart rhythm."},{"drug_id":"chlorothiazide","indication_name":"Hypertension with Left Ventricular Hypertrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diuril","generic_name":"CHLOROTHIAZIDE","company_name":"Salix Pharms","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 3","drug_class":"Thiazide Diuretic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"fludeoxyglucose","indication_name":"left ventricular dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludeoxyglucose F-18","generic_name":"FLUDEOXYGLUCOSE","company_name":"Downstate Clincl","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a radioactive sugar molecule that accumulates in cells with high metabolic activity, allowing for visualization of cancer and other conditions."},{"drug_id":"fludeoxyglucose","indication_name":"coronary artery disease and left ventricular dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludeoxyglucose F-18","generic_name":"FLUDEOXYGLUCOSE","company_name":"Downstate Clincl","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a radioactive sugar molecule that accumulates in cells with high metabolic activity, allowing for visualization of cancer and other conditions."},{"drug_id":"f-18","indication_name":"left ventricular dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludeoxyglucose F-18","generic_name":"F-18","company_name":"3D Imaging Drug","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a radioactive molecule that accumulates in areas of high metabolic activity, allowing for imaging of various conditions."},{"drug_id":"f-18","indication_name":"coronary artery disease and left ventricular dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludeoxyglucose F-18","generic_name":"F-18","company_name":"3D Imaging Drug","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a radioactive molecule that accumulates in areas of high metabolic activity, allowing for imaging of various conditions."},{"drug_id":"bretylium","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bretylium Tosylate","generic_name":"BRETYLIUM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"bretylium","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"bretylium","indication_name":"Prevention of Ventricular Fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bretylium Tosylate","generic_name":"BRETYLIUM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"bretylium","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"bretylium","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bretylium Tosylate","generic_name":"BRETYLIUM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"bretylium","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"bretylium","indication_name":"Ventricular fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bretylium Tosylate","generic_name":"BRETYLIUM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"bretylium","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"amiodarone","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cordarone","generic_name":"AMIODARONE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"sodium channels, potassium channels, calcium channels","drug_class":"Antiarrhythmic","quality_score":69,"revenue":null,"mechanism":"Amiodarone, a class III antiarrhythmic, blocks sodium, potassium, and calcium channels, prolongs cardiac action potentials, and has vasodilatory effects."},{"drug_id":"amiodarone","indication_name":"Prevention of Ventricular Fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cordarone","generic_name":"AMIODARONE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"sodium channels, potassium channels, calcium channels","drug_class":"Antiarrhythmic","quality_score":69,"revenue":null,"mechanism":"Amiodarone, a class III antiarrhythmic, blocks sodium, potassium, and calcium channels, prolongs cardiac action potentials, and has vasodilatory effects."},{"drug_id":"amiodarone","indication_name":"Ventricular fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cordarone","generic_name":"AMIODARONE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"sodium channels, potassium channels, calcium channels","drug_class":"Antiarrhythmic","quality_score":69,"revenue":null,"mechanism":"Amiodarone, a class III antiarrhythmic, blocks sodium, potassium, and calcium channels, prolongs cardiac action potentials, and has vasodilatory effects."},{"drug_id":"enalapril-maleate","indication_name":"Asymptomatic left ventricular systolic dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vasotec","generic_name":"ENALAPRIL MALEATE","company_name":"Azurity","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor","quality_score":67,"revenue":null,"mechanism":"Vasotec works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor."},{"drug_id":"acebutolol","indication_name":"Ventricular premature beats","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sectral","generic_name":"ACEBUTOLOL","company_name":"Promius Pharma","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"disopyramide","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norpace Cr","generic_name":"DISOPYRAMIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Antiarrhythmic","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"quinidine-sulfate","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quinidine Gluconate","generic_name":"QUINIDINE SULFATE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M2","drug_class":"Antiarrhythmic","quality_score":10,"revenue":null,"mechanism":"Quinidine Gluconate works by blocking the M2 muscarinic acetylcholine receptor, which helps regulate heart rhythm."},{"drug_id":"adenosine","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adenocard","generic_name":"ADENOSINE","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Adenosine receptor A3","drug_class":"Adenosine Receptor Agonist [EPC]","quality_score":43,"revenue":null,"mechanism":""},{"drug_id":"glyceryl-trinitrate","indication_name":"Left ventricular cardiac dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nitroglycerin","generic_name":"glyceryl trinitrate","company_name":"Fougera","drug_phase":"marketed","molecular_target":"guanylate cyclase","drug_class":"Nitrate Vasodilator [EPC]","quality_score":65,"revenue":null,"mechanism":"Nitroglycerin forms nitric oxide, activating guanylate cyclase and increasing cyclic GMP, leading to smooth muscle relaxation and vasodilation."},{"drug_id":"losartan-potassium","indication_name":"Hypertension with Left Ventricular Hypertrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cozaar","generic_name":"LOSARTAN POTASSIUM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Type-1 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker","quality_score":69,"revenue":null,"mechanism":"Cozaar works by blocking the action of angiotensin II on its receptor, which helps to relax blood vessels and lower blood pressure."},{"drug_id":"captopril","indication_name":"Left ventricular cardiac dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Capozide 25/15","generic_name":"CAPTOPRIL","company_name":"Aarxion Anda Hlding","drug_phase":"marketed","molecular_target":"Renin","drug_class":"Thiazide Diuretic [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"flecainide","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tambocor","generic_name":"FLECAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":59,"revenue":null,"mechanism":""},{"drug_id":"flecainide","indication_name":"Prevention of Paroxysmal Supraventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tambocor","generic_name":"FLECAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":59,"revenue":null,"mechanism":""},{"drug_id":"esmolol","indication_name":"Supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brevibloc In Plastic Container","generic_name":"ESMOLOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":63,"revenue":null,"mechanism":"Brevibloc works by blocking the beta-1 adrenergic receptor, which reduces the heart's response to stress and increases heart rate."},{"drug_id":"alprostadil","indication_name":"Aorta Dextratransposition with Intact Ventricular Septum","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caverject","generic_name":"ALPROSTADIL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Prostaglandin E2 receptor EP3 subtype","drug_class":"Prostaglandin Analog [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"verapamil-hydrochloride","indication_name":"Control of ventricular rate at rest in patients with chronic atrial flutter and/or atrial fibrillation (in association with digitalis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"verapamil-hydrochloride","indication_name":"Control of ventricular rate during stress in patients with chronic atrial flutter and/or atrial fibrillation (in association with digitalis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"verapamil-hydrochloride","indication_name":"Prophylaxis of repetitive paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"non-interventional-study","indication_name":"Paroxysmal Supraventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"non-interventional-study","indication_name":"Supraventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"non-interventional-study","indication_name":"Ventricular Arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"non-interventional-study","indication_name":"Ventricular Fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"non-interventional-study","indication_name":"Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"verapamil","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isoptin","generic_name":"VERAPAMIL","company_name":"","drug_phase":"marketed","molecular_target":"Voltage-dependent L-type calcium channel subunit alpha-1C","drug_class":"Calcium Channel Blocker","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"verapamil","indication_name":"Prevention of Paroxysmal Supraventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isoptin","generic_name":"VERAPAMIL","company_name":"","drug_phase":"marketed","molecular_target":"Voltage-dependent L-type calcium channel subunit alpha-1C","drug_class":"Calcium Channel Blocker","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"moracizine","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"moracizine","company_name":"","drug_phase":"unknown","molecular_target":"Sodium channel protein type 5 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"brevibloc","indication_name":"Supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Brevibloc","company_name":"AOP Orphan Pharmaceuticals AG","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"sotalol","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betapace","generic_name":"sotalol","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Potassium voltage-gated channel subfamily H member 2","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"lignocaine","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lignocaine","company_name":"University of Malaya","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"mexiletine","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mexitil","generic_name":"MEXILETINE","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2B","drug_class":"Antiarrhythmic","quality_score":66,"revenue":null,"mechanism":"Mexitil works by blocking abnormal electrical signals in the heart to restore a normal heartbeat."},{"drug_id":"lidocaine-hydrochloride","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lignospan Forte","generic_name":"Lidocaine Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"neuronal membrane ionic channels","drug_class":"local anesthetic, amide type","quality_score":68,"revenue":null,"mechanism":"Lidocaine stabilizes neuronal membrane by inhibiting ionic fluxes required for impulse initiation and conduction."},{"drug_id":"ethacizine","indication_name":"Supraventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Etacizin","generic_name":"ethacizine","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"ethacizine","quality_score":null,"revenue":null,"mechanism":"Etacizin works by blocking potassium channels in the heart, which helps to regulate abnormal heart rhythms."},{"drug_id":"ethacizine","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Etacizin","generic_name":"ethacizine","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"ethacizine","quality_score":null,"revenue":null,"mechanism":"Etacizin works by blocking potassium channels in the heart, which helps to regulate abnormal heart rhythms."},{"drug_id":"procaine","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isocain","generic_name":"PROCAINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A","drug_class":"Amide Local Anesthetic [EPC]","quality_score":34,"revenue":null,"mechanism":""},{"drug_id":"detajmium","indication_name":"Supraventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tachmalcor","generic_name":"detajmium","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"detajmium","quality_score":null,"revenue":null,"mechanism":"Tachmalcor works by stabilizing cardiac ion channels to regulate abnormal heart rhythms."},{"drug_id":"detajmium","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tachmalcor","generic_name":"detajmium","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"detajmium","quality_score":null,"revenue":null,"mechanism":"Tachmalcor works by stabilizing cardiac ion channels to regulate abnormal heart rhythms."},{"drug_id":"aprindine","indication_name":"Supraventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fiboran","generic_name":"APRINDINE","company_name":"","drug_phase":"marketed","molecular_target":"Cytochrome P450 2D6","drug_class":"aprindine","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"aprindine","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fiboran","generic_name":"APRINDINE","company_name":"","drug_phase":"marketed","molecular_target":"Cytochrome P450 2D6","drug_class":"aprindine","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"diltiazem","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cardizem","generic_name":"diltiazem","company_name":"Generic (originally Tanabe Seiyaku)","drug_phase":"marketed","molecular_target":"Voltage-dependent calcium channel gamma-1 subunit, Multidrug resistance protein 1, Solute carrier family 22 member 1","drug_class":"Calcium channel blocker (non-dihydropyridine, benzothiazepine)","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"enalapril","indication_name":"Asymptomatic left ventricular systolic dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vasotec","generic_name":"enalapril","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme, Angiotensin-converting enzyme","drug_class":"ACE inhibitor","quality_score":60,"revenue":null,"mechanism":"ACE inhibitor prodrug that is converted to enalaprilat, blocking angiotensin-converting enzyme to lower blood pressure."},{"drug_id":"landiolol","indication_name":"Hemodynamically unstable ventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onoact","generic_name":"LANDIOLOL","company_name":"Aop Hlth Us","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"landiolol","quality_score":37,"revenue":null,"mechanism":"Onoact works by blocking the beta-1 adrenergic receptor, which helps to slow down abnormal heart rhythms."},{"drug_id":"landiolol","indication_name":"Supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onoact","generic_name":"LANDIOLOL","company_name":"Aop Hlth Us","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"landiolol","quality_score":37,"revenue":null,"mechanism":"Onoact works by blocking the beta-1 adrenergic receptor, which helps to slow down abnormal heart rhythms."},{"drug_id":"verapamil-hydrochloride","indication_name":"Prophylaxis of paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"hydrochlorothiazide","indication_name":"Hypertension with Left Ventricular Hypertrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Microzide","generic_name":"hydrochlorothiazide","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"ACE","drug_class":"Thiazide Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":"Lisinopril inhibits ACE, reducing angiotensin II and aldosterone, leading to lower blood pressure."},{"drug_id":"losartan","indication_name":"Hypertension with Left Ventricular Hypertrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cozaar","generic_name":"losartan","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"AT1 receptor","drug_class":"ARB (Angiotensin II receptor blocker)","quality_score":65,"revenue":null,"mechanism":"Losartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 receptor."},{"drug_id":"propranolol","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inderal","generic_name":"propranolol","company_name":"Generic (originally ICI/AstraZeneca)","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2","drug_class":"Non-selective beta-blocker","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"propranolol","indication_name":"Supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inderal","generic_name":"propranolol","company_name":"Generic (originally ICI/AstraZeneca)","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2","drug_class":"Non-selective beta-blocker","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"carvedilol","indication_name":"Left ventricular cardiac dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coreg","generic_name":"CARVEDILOL","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"alpha-Adrenergic Blocker [EPC]","quality_score":70,"revenue":null,"mechanism":"Coreg works by blocking the effects of the hormone epinephrine on the heart, reducing its workload and improving its function."},{"drug_id":"norpace","indication_name":"Documented ventricular arrhythmias","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norpace Cr","generic_name":"Disopyramide Phosphate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"G protein-activated inward rectifier potassium channel 4","drug_class":"High Risk QT Prolonging Agents","quality_score":10,"revenue":null,"mechanism":"Norpace is a sodium channel blocker and a Class 1a anti-arrhythmic agent."},{"drug_id":"norpace","indication_name":"Sustained ventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norpace Cr","generic_name":"Disopyramide Phosphate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"G protein-activated inward rectifier potassium channel 4","drug_class":"High Risk QT Prolonging Agents","quality_score":10,"revenue":null,"mechanism":"Norpace is a sodium channel blocker and a Class 1a anti-arrhythmic agent."},{"drug_id":"norpace","indication_name":"Life-threatening ventricular arrhythmias","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norpace Cr","generic_name":"Disopyramide Phosphate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"G protein-activated inward rectifier potassium channel 4","drug_class":"High Risk QT Prolonging Agents","quality_score":10,"revenue":null,"mechanism":"Norpace is a sodium channel blocker and a Class 1a anti-arrhythmic agent."},{"drug_id":"enalaprilat","indication_name":"Asymptomatic left ventricular systolic dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vasotec","generic_name":"ENALAPRILAT","company_name":"Biovail Labs Intl","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"enalaprilat","quality_score":75,"revenue":null,"mechanism":"Vasotec works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor."},{"drug_id":"prajmalium","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prajmaline","generic_name":"PRAJMALIUM","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"prajmalium","quality_score":null,"revenue":null,"mechanism":"Prajmaline works by blocking sodium channels in the heart, which helps to regulate abnormal heart rhythms."},{"drug_id":"isoprenaline","indication_name":"Atrioventricular block","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isuprel","generic_name":"isoprenaline","company_name":"","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta-Adrenergic Agonist","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"adenosine-triphosphate","indication_name":"Supraventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Triphosphoric Acid Adenosine Ester","generic_name":"ADENOSINE TRIPHOSPHATE","company_name":"","drug_phase":"marketed","molecular_target":"P2X purinoceptor 3","drug_class":"Vitamin C [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"ganciclovir","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytovene","generic_name":"GANCICLOVIR","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Metabotropic glutamate receptor 1","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication."},{"drug_id":"methoxamine","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methoxamin","generic_name":"METHOXAMINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor","drug_class":"methoxamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ramipril","indication_name":"Left ventricular cardiac dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Altace","generic_name":"RAMIPRIL","company_name":"King Pfizer","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Altace works by blocking the action of angiotensin-converting enzyme, a key player in the renin-angiotensin-aldosterone system that regulates blood pressure."},{"drug_id":"adenosin","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adenosin","company_name":"University of Roma La Sapienza","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 4-kinase type 2-alpha, Phosphatidylinositol 4-kinase type 2-beta, Adenosine kinase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lidocain","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lidocain","company_name":"Bayer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"nitroglycerine","indication_name":"Left ventricular cardiac dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"nitroglycerine","company_name":"University Hospital, Ghent","drug_phase":"marketed","molecular_target":"Atrial natriuretic peptide receptor 1, Soluble guanylate cyclase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prostavasin","indication_name":"Aorta Dextratransposition with Intact Ventricular Septum","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prostavasin","company_name":"Hannover Medical School","drug_phase":"phase_2","molecular_target":"Cation channel sperm-associated protein 1, Cation channel sperm-associated protein 2, Cation channel sperm-associated protein 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mavik","indication_name":"Left ventricular cardiac dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mavik","company_name":"Dr. Reddy's Laboratories Limited","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xylocain","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"xylocain","company_name":"Saint-Joseph University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"landiolol","indication_name":"Ventricular fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onoact","generic_name":"LANDIOLOL","company_name":"Aop Hlth Us","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"landiolol","quality_score":37,"revenue":null,"mechanism":"Onoact works by blocking the beta-1 adrenergic receptor, which helps to slow down abnormal heart rhythms."}],"pipeline":[{"drug_id":"oral-anticoagulant","indication_name":"Left ventricular thrombus","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oral Anticoagulant","generic_name":"oral-anticoagulant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Factor Xa (coagulation Factor X, activated form)","drug_class":"Direct oral anticoagulant (DOAC); Factor Xa inhibitor","quality_score":31,"revenue":null,"mechanism":"Inhibits Factor Xa to block the intrinsic and extrinsic coagulation pathways, preventing thrombin generation and clot formation."}],"offLabel":[],"totalMarketed":87,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT04024865","title":"Domperidone and Risk of Serious Cardiac Events in Postpartum Women","phase":"","overall_status":"COMPLETED","enrollment_count":184929,"lead_sponsor_name":"Canadian Network for Observational Drug Effect Studies, CNODES","has_results":false},{"nct_id":"NCT07515859","title":"Risk Stratification of Cancer Therapy-Related Cardiac Dysfunction Using AI-Enhanced Electrocardiography","phase":"","overall_status":"COMPLETED","enrollment_count":31486,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT07263204","title":"AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06763549","title":"COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":15000,"lead_sponsor_name":"Peerbridge Health, Inc","has_results":false},{"nct_id":"NCT06607471","title":"Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Scientific Institute San Raffaele","has_results":false},{"nct_id":"NCT05117970","title":"Artificial Intelligence-assisted Diagnosis and Prognostication in Low Ejection Fraction Using Electrocardiograms","phase":"NA","overall_status":"COMPLETED","enrollment_count":13631,"lead_sponsor_name":"National Defense Medical Center, Taiwan","has_results":false},{"nct_id":"NCT06968533","title":"ECG Low Ejection Fraction Detection and Guiding in AI Navigated Treatment Era","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":13350,"lead_sponsor_name":"National Defense Medical Center, Taiwan","has_results":false},{"nct_id":"NCT05867407","title":"A Multicenter Pragmatic Implementation Study of ECG-AI-Based Clinical Decision Support Software to Identify Low LVEF","phase":"NA","overall_status":"TERMINATED","enrollment_count":11610,"lead_sponsor_name":"Anumana, Inc.","has_results":false},{"nct_id":"NCT04189822","title":"Hearts in Rhythm Organization (HiRO)National Registry and Bio Bank","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10000,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT07096973","title":"Cardiac REhabilitation COhort at the Medicine Campus DaVos to invEstigate Recovery","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Hochgebirgsklinik Davos","has_results":false},{"nct_id":"NCT06324682","title":"ConTempoRary Cardiac Stimulation in Clinical practicE: lEft, BivEntriculAr, Right, and conDuction System Pacing","phase":"","overall_status":"RECRUITING","enrollment_count":8400,"lead_sponsor_name":"University Hospital of Ferrara","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT07375602","title":"A Multimodal AI Prediction Model for Complications After Transcatheter Closure of Perimembranous VSD in Children","phase":"","overall_status":"RECRUITING","enrollment_count":5249,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT06748261","title":"AI-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary CTA","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT05965375","title":"Risk Stratification Value of Biomarkers in Patients With Ventricular Arrhythmias","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT05521451","title":"Clinical Cohort Study - TRUST","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT05829993","title":"Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07355023","title":"AI-Enabled Electrocardiogram-Guided Guideline-Directed Medical Therapy on Incident Left Ventricular Dysfunction: A Target Trial Emulation Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Tri-Service General Hospital","has_results":false},{"nct_id":"NCT04189471","title":"Improving Outcomes for Patients With Life-Threatening Neurologic Illness","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT05903313","title":"A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software","phase":"","overall_status":"UNKNOWN","enrollment_count":4306,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT06739057","title":"Pediatric Ventricle Function Assessment Study","phase":"","overall_status":"COMPLETED","enrollment_count":3993,"lead_sponsor_name":"HBI Solutions Inc.","has_results":false},{"nct_id":"NCT07354347","title":"Optimal Settings for Anti Tachycardia Pacing (ATP) on ICD","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":3980,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT03210883","title":"Global Electrical Heterogeneity and Clinical Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":3471,"lead_sponsor_name":"Larisa Tereshchenko","has_results":false},{"nct_id":"NCT05815745","title":"\"Physiological vs Right Ventricular Pacing Outcome Trial Evaluated for bradyCardia Treatment\" (PROTECT-HF)","phase":"NA","overall_status":"RECRUITING","enrollment_count":2600,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT05835791","title":"END - VT Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":2454,"lead_sponsor_name":"Nova Scotia Health Authority","has_results":false},{"nct_id":"NCT00358215","title":"RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2278,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03786497","title":"Protecting Brains and Saving Futures - the PBSF Protocol","phase":"","overall_status":"UNKNOWN","enrollment_count":2268,"lead_sponsor_name":"Protecting Brains Saving Futures","has_results":false},{"nct_id":"NCT04496518","title":"Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2200,"lead_sponsor_name":"Medtronic","has_results":false},{"nct_id":"NCT05650658","title":"Left vs Left Randomized Clinical Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":2136,"lead_sponsor_name":"Baylor College of Medicine","has_results":false},{"nct_id":"NCT06811519","title":"AI-based Prediction of Cardiac Function Using Echocardiography and Body Composition Data (ECHO-FIT Study)","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT06964464","title":"Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT06504056","title":"Risk Stratification and Early Prevention Strategies for Non-compaction of Ventricular Myocardium (CAPTAIN)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT03076580","title":"An Integrative-\"Omics\" Study of Cardiomyopathy Patients for Diagnosis and Prognosis in China","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Beijing Institute of Heart, Lung and Blood Vessel Diseases","has_results":false},{"nct_id":"NCT03853369","title":"Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Sichuan Baili Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04848844","title":"The PAtients pResenTing With COngenital HeaRt DIseAse Register (ARTORIA-R)","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT03821051","title":"China Structural Ventricular Arrhythmias Registry","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"China National Center for Cardiovascular Diseases","has_results":false},{"nct_id":"NCT05010655","title":"Low Ejection Fraction in Single Lead ECG","phase":"","overall_status":"COMPLETED","enrollment_count":1935,"lead_sponsor_name":"Eko Devices, Inc.","has_results":false},{"nct_id":"NCT03735251","title":"Epidemic Profile of Left Ventricular Diastoic Dysfunction in the Community Elderly and Establishing Prediction Model: the Northern Shanghai Study","phase":"","overall_status":"COMPLETED","enrollment_count":1920,"lead_sponsor_name":"Ya-Wei Xu","has_results":false},{"nct_id":"NCT06269692","title":"MAgnetic Resonance Imaging-guided implanTation of Cardioverter DEFibrillators","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1812,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT03243604","title":"cARdiotoxicity Profile of aBIraTeRone in prostAte Cancer : a pharmacoviGilancE Study","phase":"","overall_status":"COMPLETED","enrollment_count":1717,"lead_sponsor_name":"Groupe Hospitalier Pitie-Salpetriere","has_results":false},{"nct_id":"NCT06343844","title":"Disparities in Myocardial Infarction Remodeling According to Gender","phase":"NA","overall_status":"RECRUITING","enrollment_count":1650,"lead_sponsor_name":"University Hospital, Angers","has_results":false},{"nct_id":"NCT06231797","title":"AI-ECG Screening for Left Ventricular Systolic Dysfunction","phase":"","overall_status":"UNKNOWN","enrollment_count":1530,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT02155907","title":"Atrial Fibrillation Detected by ELR and Holter Recording, a Comparison in Patients With Ischemic Stroke or TIA","phase":"","overall_status":"COMPLETED","enrollment_count":1507,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT07501481","title":"Arrhythmic Risk in Myocarditis Outcome Research","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"AZ Sint-Jan AV","has_results":false},{"nct_id":"NCT07149701","title":"Ventricular Tachycardia Cohort","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT07291544","title":"Management of Supraventricular Tachycardias in Children","phase":"","overall_status":"COMPLETED","enrollment_count":1400,"lead_sponsor_name":"Paris Cardiovascular Research Center (Inserm U970)","has_results":false},{"nct_id":"NCT04474223","title":"Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1300,"lead_sponsor_name":"NYU Langone Health","has_results":false},{"nct_id":"NCT05647577","title":"The Relationship Between Inflammatory ARTritis and CArdiac DIseAse","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1285,"lead_sponsor_name":"University Hospital, Gentofte, Copenhagen","has_results":false},{"nct_id":"NCT07279870","title":"RandomIsed sTudy of Physiologic cArdiac stimuLation in patIents With Atrio-ventricular Conduction Disease","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1260,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT04400435","title":"Detection of Heart Conditions With Single Lead ECG Using Artificial Intelligence","phase":"","overall_status":"COMPLETED","enrollment_count":1258,"lead_sponsor_name":"Eko Devices, Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}